GlassScriptPhysician profile
Nancy Rose Mcdowell
NPI 1710234398
$12,441.54
in general payments reported to CMS, 2019-2025
50 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,617 · 2022: $3,082 · 2023: $2,178 · 2024: $2,230 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,618 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,617.98 |
| Education | $124.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,537.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,574.48 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $717.52 | 2021-2025 | |
| Pfizer INC. | $420.23 | 2021-2025 | |
| Amgen INC. | $395.60 | 2021-2025 | Prolia, Evenity, Krystexxa |
| Amarin Pharma, INC. | $394.95 | 2021-2022 | |
| Glaxosmithkline, LLC. | $390.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.62 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $366.91 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $364.53 | 2022-2025 | |
| Nevro Corp. | $327.47 | 2021-2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.83 | 2021-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $302.95 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $294.51 | 2021-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $292.78 | 2022-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $291.85 | 2021-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $277.36 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $256.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $254.63 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $212.57 | 2021-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $210.31 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $193.71 | 2021-2025 | Verquvo, Capvaxive |
| Exact Sciences Corporation | $182.66 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $173.30 | 2022-2025 | Korlym |
| Abbott Laboratories | $148.62 | 2021-2023 | Freestyle Libre |
| Idorsia Pharmaceuticals US INC | $131.26 | 2022-2024 | Quviviq |
| Pulmonx Corporation | $123.99 | 2022 | |
| Scpharmaceuticals INC. | $113.72 | 2025 | |
| Shield Therapeutics INC | $102.18 | 2023-2025 | Accrufer |
| Mylan Specialty L.P. | $84.90 | 2022 | |
| Ardelyx, INC. | $67.66 | 2024-2025 | Ibsrela |
| Antares Pharma, INC. | $59.35 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceuticals, INC. | $55.62 | 2021 | |
| Radius Health, INC. | $53.69 | 2024 | Tymlos |
| Phathom Pharmaceuticals, INC. | $48.58 | 2024-2025 | Voquezna |
| Phadia US INC. | $34.86 | 2023 | Immunocap |
| Lundbeck LLC | $34.63 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $30.85 | 2025 | Contrave |
| Halozyme INC | $24.72 | 2023 | |
| Baxter Healthcare | $24.21 | 2022 | |
| Verona Pharma, INC. | $22.08 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $20.97 | 2023 | |
| Genentech USA, INC. | $19.30 | 2021 | |
| Mannkind Corporation | $18.80 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.66 | 2022 | |
| Corium, LLC | $16.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.59 | 2025 | Unithroid |
| Bioventus LLC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.